By Richard Knox The Food and Drug Administration plans to review the use of the popular anti-anemia drugs Epogen, Procrit and Aranesp because of persistent evidence they can raise the risk of heart attacks, strokes and cardiovascular death. Magnified
Read More...
Read the complete post at http://www.npr.org/blogs/health/2010/01/fda_to_review_popular_bloodsti.html?ft=1&f=103537970
Posted
Jan 07 2010, 11:29 AM
by
NPR Blogs: Shots - Health News